MONTPELLIER, France–(BUSINESS WIRE)–Regulatory News: MedinCell (Paris:MEDCL) Christophe Douat, CEO of MedinCell, said: “Coverage initiation by Jefferies confirms the growing interest in MedinCell by leading players in the US biopharmaceutical sector. It is part of our strategy to increase Medincell’s visibility in the US.” The initiation of coverage by Jefferies occurs as MedinCell has recently reached commercial stage with the market launch by Teva of UZEDY™ for the treatment of schizophreni
Business Wire Stock Sale/Buyback News
